ARTICLE | Company News
SciClone other research news
May 3, 1999 7:00 AM UTC
SCLN received a $517,000 grant from the Cystic Fibrosis Foundation for its ongoing Phase II study to evaluate safety, efficacy and optimal dose of its CPX oral small molecule. ...